SAN FRANCISCO, Jan. 3, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, today announced that it has appointed Eric B. Mosbrooker
as Senior Vice President and Chief Commercial Officer. In
this role, Mr. Mosbrooker is responsible for leading the
development and execution of the global commercial strategy for the
company's growing portfolio of gene therapy product candidates, and
for building the commercial organization, including patient
services, sales, marketing, and market access teams.
"Eric is an established leader with a demonstrated track-record
of building global commercial organizations and successfully
launching rare disease products," stated Matthew R. Patterson, Chairman and Chief
Executive Officer. "We are excited to welcome Eric to the
Audentes team and look forward to benefitting from his substantial
experience and expertise as we build the commercial capabilities
needed to execute on our vision to be a global leader in AAV-based
genetic medicines for rare diseases."
Mr. Mosbrooker has held numerous leadership roles throughout his
more than 15 years in the healthcare industry, with the majority of
his tenure focused on launching and commercializing treatments for
rare and orphan diseases. Mr. Mosbrooker joins Audentes from
Origin Biosciences, a subsidiary of BridgeBio Pharma and a
biotechnology company focused on developing a treatment for
molybdenum cofactor deficiency (MoCD) type A, a rare pediatric
metabolic disorder, where he served as Chief Operating
Officer. Prior to Origin Biosciences, Mr. Mosbrooker led the
orphan business at Horizon Pharma after its acquisition of Raptor
Pharmaceuticals. At Raptor, he was the Senior Vice President
of Americas & Asia Pacific,
where he led the U.S. launch of PROCYSBI®, a drug for
the treatment of nephropathic cystinosis. Previously, Mr.
Mosbrooker served as the lead for commercial operations and market
access for STRENSIQ® at Alexion and Enobia Pharma,
Inc. He also served in various commercial operational
capacities at Onyx Pharmaceuticals, Jazz Pharmaceuticals Inc.,
Chiron Corporation (now Novartis), and Millennium
Pharmaceuticals. Mr. Mosbrooker earned his B.S. in industrial
engineering from the University of Wisconsin,
Madison.
"This is an exciting time to join Audentes," stated Mr.
Mosbrooker. "I look forward to building and leading a
top-tier commercial organization that can deliver innovative
therapies with the potential to provide transformative benefit to
patients."
In connection with Mr. Mosbrooker's appointment, effective
January 3, 2018, the company's
compensation committee granted him 87,750 stock options and 31,500
restricted stock units as an inducement to employment pursuant to
Nasdaq Listing Rule 5635(c)(4). The exercise price of the
inducement stock option will be the closing price of the company's
common stock on the grant date. Each equity award will vest with
respect to 25% of the award on the first anniversary of the grant
date, with the remaining portion of the equity award vesting
monthly thereafter, subject to Mr. Mosbrooker's continued
service.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing innovative gene therapy products for
patients living with serious, life-threatening rare diseases.
We are currently conducting Phase 1/2 clinical studies of our lead
product candidates, AT132 for the treatment of X-linked Myotubular
Myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, AT982 for the treatment of Pompe disease, and AT307
for the treatment of the CASQ2 subtype of catecholaminergic
polymorphic ventricular tachycardia (CASQ2-CPVT). We are a
focused, experienced and passionate team committed to forging
strong, global relationships with the patient, research and medical
communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to: the timing and nature of clinical
development activities, the timing of regulatory submissions or
approvals, and the expected safety and efficacy profile of the
company's product candidates. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. Although the company believes that
the expectations reflected in such forward-looking statements are
reasonable, the company cannot guarantee future events, results,
actions, levels of activity, performance or achievements, and the
timing and results of biotechnology development and potential
regulatory approval is inherently uncertain. Forward-looking
statements are subject to risks and uncertainties that may cause
the company's actual activities or results to differ significantly
from those expressed in any forward-looking statement, including
risks and uncertainties related to the company's ability to advance
its product candidates, obtain regulatory approval of and
ultimately commercialize its product candidates, the timing and
results of preclinical and clinical trials, the company's ability
to fund development activities and achieve development goals,
establish and scale-up manufacturing processes that comply with
regulatory requirements, protect intellectual property and
other risks and uncertainties described under the heading
"Risk Factors" in documents the company files from time to time
with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to revise or
update any forward-looking statements to reflect events or
circumstances after the date hereof.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-appoints-eric-b-mosbrooker-as-senior-vice-president-and-chief-commercial-officer-300770424.html
SOURCE Audentes Therapeutics, Inc.